April 24th, 2020 | 07:36 CEST
BioNTech, Gilead, Memphasys - in the spotlight of investors overnight
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Growing billion dollar market
The desire of couples to have children tends to occur increasingly later in modern society. Often professional or economic reasons are in the foreground before the family picture is rounded off with their own children. However, the chances of a successful natural pregnancy decrease with increasing age. Often couples with increasing frustration then consult appropriate experts to deal with the subject of artificial insemination.
Solution increases chances of success
The Australian company Memphasys has developed a product called FELIX, which separates the high-quality sperm from the man's seminal fluid and thus increases the chances of success of artificial insemination. The advantage of FELIX is that the process only takes a few minutes and the costs of treatment can be reduced. The product is to be launched in several countries in the second half of 2020. The market for artificial insemination is growing steadily and any solution that statistically increases the chances of a successful pregnancy will be in high demand.
Memphasys shares are traded in Australia and Germany and at a price of AUD 0.048 the company has a market capitalization of AUD 36 million. Further details of the FELIX launch should increase interest in Memphasys. Introduction at the right time could be worthwhile. Further information is available in the following video interview with Executive Chairman Alison Coutts: youtu.be/kHA-UhbeZH8
Success and failure
BioNTech from Germany is currently working with Pfizer on the search for a vaccine against COVID-19. The news that tests are now being carried out on 200 people in order to obtain marketing authorisation if successful, has boosted the company's share price. The valuation of BioNTech has now risen to over EUR 10 billion. However, should the success fail to materialise, the disappointment is likely to be great.
A report on Gilead Science that the drug Remdesiver did not achieve the desired success in tests in connection with the treatment of Corona patients has caused the share price to fall and the value of the company has slid back below the USD 100 billion mark. It seems that the pandemic issue will be with us for some time to come.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.